{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:35Z","timestamp":1791343475326,"version":"4.3.1"},"reference-count":83,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas and include 3 different subtypes\u2014namely, extranodal (EMZL), nodal, and splenic (SMZL). The initial assessment requires specific diagnostic and staging procedures depending on organ-related peculiarities. In particular, although positron emission tomography\/computed tomography was not initially recommended, recent data have reassessed its role in the routine staging of MZL, especially when only localized treatment is planned or there is a suspicion of histologic transformation. Recent findings have improved the risk stratification of MZL patients, highlighting the association of early progression after frontline therapy with worse overall survival. A significant fraction of MZL cases may be related to specific bacterial (ie, Helicobacter pylori in gastric EMZL) or viral infections (hepatis C virus), and in the earlier phases of disease, a variable percentage of patients may respond to anti-infective therapy. Involved-site radiotherapy has a central role in the management of localized EMZL not amenable to or not responding to anti-infective therapy. Although rituximab-based treatments (bendamustine- rituximab in advanced EMZL or rituximab monotherapy in SMZL) have demonstrated favorable results, the current therapeutic scenario is predicted to rapidly change as emerging novel agents, especially Bruton's tyrosine kinase inhibitors, have demonstrated promising efficacy and safety profiles, leading to their approval in the relapsed setting. Moreover, a large variety of novel agents (phosphatidylinositol 3-kinase inhibitors, chimeric antigen receptor T-cells, bispecific antibodies) are being tested in MZL patients with encouraging preliminary results.<\/jats:p>","DOI":"10.1182\/hematology.2022000362","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:15:12Z","timestamp":1670602512000},"page":"676-687","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Management of marginal zone lymphomas"],"prefix":"10.1182","volume":"2022","author":[{"given":"Michele","family":"Merli","sequence":"first","affiliation":[{"name":"1 Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"2 Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"3 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"March","key":"2022121313282026000_hem2022000362C1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"20","key":"2022121313282026000_hem2022000362C2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2022121313282026000_hem2022000362C3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2022121313282026000_hem2022000362C4","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood-2013-07-515155","article-title":"Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?","volume":"123","author":"Xochelli","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2022121313282026000_hem2022000362C5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00277-018-3501-8","article-title":"Burden of illness of follicular lymphoma and marginal zone lymphoma","volume":"98","author":"Monga","year":"2019","journal-title":"Ann Hematol"},{"issue":"17","key":"2022121313282026000_hem2022000362C6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313282026000_hem2022000362C7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2022121313282026000_hem2022000362C8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2022121313282026000_hem2022000362C9","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2022121313282026000_hem2022000362C10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2022121313282026000_hem2022000362C11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2022121313282026000_hem2022000362C12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2022121313282026000_hem2022000362C13","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2022121313282026000_hem2022000362C14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non- follicular indolent B-cell lymphomas","volume":"94","author":"Tracy","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2022121313282026000_hem2022000362C15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.25446","article-title":"Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation","volume":"94","author":"Alderuccio","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2022121313282026000_hem2022000362C16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"2022121313282026000_hem2022000362C17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2022121313282026000_hem2022000362C18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"issue":"27","key":"2022121313282026000_hem2022000362C19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022121313282026000_hem2022000362C20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.clml.2019.10.006","article-title":"18F-FDG PET\/CT or PET role in MALT lymphoma: an open issuel not yet solved\u2014a critical review","volume":"20","author":"Albano","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2022121313282026000_hem2022000362C21","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1002\/cam4.3096","article-title":"Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: a single center analysis","volume":"9","author":"Husnain","year":"2020","journal-title":"Cancer Med"},{"issue":"10","key":"2022121313282026000_hem2022000362C22","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00261-018-1542-z","article-title":"18F-FDG PET\/CT in splenic marginal zone lymphoma","volume":"43","author":"Albano","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"2022121313282026000_hem2022000362C23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.2578","article-title":"FDG PET\/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma","volume":"37","author":"Vaxman","year":"2019","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2022121313282026000_hem2022000362C24","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2019-126068","article-title":"Utility and patterns of use of PET\/CT and bone marrow biopsy for staging in non-Hodgkin lymphoma in the clinical setting: a retrospective analysis using the LEO database","volume":"134","author":"Strouse","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2022121313282026000_hem2022000362C25","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.2019003236","article-title":"Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?","volume":"135","author":"Alderuccio","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2022121313282026000_hem2022000362C26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas\u2020","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"2022121313282026000_hem2022000362C27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution [published online 12 October 2018]","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022121313282026000_hem2022000362C28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.17815","article-title":"Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation","volume":"196","author":"Bastidas-Mora","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"2022121313282026000_hem2022000362C29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2022121313282026000_hem2022000362C30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"2022121313282026000_hem2022000362C31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2022121313282026000_hem2022000362C32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"2022121313282026000_hem2022000362C33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"21","key":"2022121313282026000_hem2022000362C34","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2022121313282026000_hem2022000362C35","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","article-title":"Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"34","author":"Frigeni","year":"2020","journal-title":"Leukemia"},{"key":"2022121313282026000_hem2022000362C36","article-title":"Direct-acting antivirals as primary treatment for hepatitis C virus\u2014associated indolent non-Hodgkin lymphomas: the BArT study of the Fondazione Italiana Linfomi [published online 17 June 2022]","author":"Merli","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022121313282026000_hem2022000362C37","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series\u2606","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"2022121313282026000_hem2022000362C38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"2022121313282026000_hem2022000362C39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"2022121313282026000_hem2022000362C40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2022121313282026000_hem2022000362C41","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"2022121313282026000_hem2022000362C42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"2022121313282026000_hem2022000362C43","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","article-title":"Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy","volume":"23","author":"Ferreri","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"2022121313282026000_hem2022000362C44","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2022121313282026000_hem2022000362C45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/CAD.0b013e32830b58c4","article-title":"Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?","volume":"19","author":"Decaudin","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2022121313282026000_hem2022000362C46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2141.2008.07112.x","article-title":"Ocular adnexal lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis","volume":"142","author":"Matthews","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2022121313282026000_hem2022000362C47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08429.x","article-title":"Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients","volume":"152","author":"Bayraktar","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"2022121313282026000_hem2022000362C48","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2022121313282026000_hem2022000362C49","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J Cutan Pathol"},{"issue":"12","key":"2022121313282026000_hem2022000362C50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/modpathol.2008.159","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States","volume":"21","author":"Takino","year":"2008","journal-title":"Mod Pathol"},{"issue":"12","key":"2022121313282026000_hem2022000362C51","first-page":"1379","article-title":"Borrelia burgdorferi in prim\u00e4r kutanen Lymphomen: eine systematische \u00dcbersicht und Metaanalyse","volume":"18","author":"Travaglino","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"2022121313282026000_hem2022000362C52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","author":"Lecuit","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"2022121313282026000_hem2022000362C53","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/annonc\/mds623","article-title":"Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study","volume":"24","author":"Wirth","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"2022121313282026000_hem2022000362C54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group Guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2022121313282026000_hem2022000362C55","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"2022121313282026000_hem2022000362C56","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"2022121313282026000_hem2022000362C57","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"2022121313282026000_hem2022000362C58","doi-asserted-by":"crossref","DOI":"10.1002\/hon.79_2879","article-title":"Phase II trial of rituximab plus chlorambucil followed by a 2-year subcutaneous rituximab maintenance in MALT lymphoma patients (IELSG38) [published online June 2021]","volume":"39","author":"Pirosa","year":"2021","journal-title":"Hematol Oncol"},{"issue":"3","key":"2022121313282026000_hem2022000362C59","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold","year":"2022","journal-title":"HemaSphere"},{"issue":"17","key":"2022121313282026000_hem2022000362C60","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2022121313282026000_hem2022000362C61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2022121313282026000_hem2022000362C62","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"issue":"17","key":"2022121313282026000_hem2022000362C63","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2022121313282026000_hem2022000362C64","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO","volume":"182","author":"Avivi","year":"2018","journal-title":"Br J Haematol"},{"issue":"16","key":"2022121313282026000_hem2022000362C65","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2022121313282026000_hem2022000362C66","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2022121313282026000_hem2022000362C67","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022121313282026000_hem2022000362C68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2022121313282026000_hem2022000362C69","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/10428194.2021.1983569","article-title":"The double significance of idelalisib immune-related toxicity","volume":"62","author":"Merli","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2022121313282026000_hem2022000362C70","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15","key":"2022121313282026000_hem2022000362C71","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022121313282026000_hem2022000362C72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-134451","article-title":"Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204)","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"issue":"14","key":"2022121313282026000_hem2022000362C73","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022121313282026000_hem2022000362C74","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2021-145640","article-title":"Completed induction phase analysis of magnify: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"138","author":"Lansigan","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313282026000_hem2022000362C75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2021-148473","article-title":"Long-term follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory (r\/r) indolent non-Hodgkin lymphoma (iNHL)","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2022121313282026000_hem2022000362C76","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"2022121313282026000_hem2022000362C77","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V120.21.3691.3691","article-title":"Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma (MALT-2008\u201301)","volume":"120","author":"Salar","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2022121313282026000_hem2022000362C78","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"2022121313282026000_hem2022000362C79","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","article-title":"Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)","volume":"36","author":"Rummel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022121313282026000_hem2022000362C80","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10428194.2020.1855344","article-title":"Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas","volume":"62","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2022121313282026000_hem2022000362C81","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022121313282026000_hem2022000362C82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","volume":"5","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2022121313282026000_hem2022000362C83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2021-147425","article-title":"The combination of umbralisib plus ublituximab is active in patients with relapsed or refractory marginal zone lymphoma (MZL): results from the phase 2 Global Unity-NHL trial","volume":"138","author":"Chavez","year":"2021","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/676\/2022985\/676merli.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/676\/2022985\/676merli.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:29:25Z","timestamp":1670938165000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/676\/493480\/Management-of-marginal-zone-lymphomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000362","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}